Abstract
Cisplatin has become one of the most commonly used compounds for the treatment of a wide spectrum of human malignancies. Unfortunately, cisplatin has several major drawbacks. Driven by the impressive impact of cisplatin on cancer chemotherapy, great efforts have been made to develop new derivatives with improved pharmacological properties. Among the over 30 platinum agents which have entered clinical trials after the onset of clinical studies with cisplatin in the early 1970s, only carboplatin and oxaliplatin have received worldwide approval so far, nedaplatin, lobaplatin and heptaplatin have gained regionally limited approval. It has become quite evident that mere analogues of cisplatin or carboplatin will not probably offer any substantial clinical advantages over the existing drugs. Therefore, people turned to synthesize non-classical platinum anticancer drugs which were capable of forming a different range of DNA adducts which could display a different spectrum of anticancer activity compared to cisplatin. This review will summarize the structural types and structure-activity rules of non-classical bi- and multi-nuclear platinum anticancer drugs, and discuss their future potential as anticancer agents.
Keywords: Anticancer, platinum(II) complexes, binuclear platinum(II) complexes, multinuclear platinum(II) complexes
Anti-Cancer Agents in Medicinal Chemistry
Title: Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development
Volume: 10 Issue: 4
Author(s): Jinchao Zhang, Liwei Wang, Zhiyong Xing, Dandan Liu, Jing Sun, Xiaoliu Li and Ying Zhang
Affiliation:
Keywords: Anticancer, platinum(II) complexes, binuclear platinum(II) complexes, multinuclear platinum(II) complexes
Abstract: Cisplatin has become one of the most commonly used compounds for the treatment of a wide spectrum of human malignancies. Unfortunately, cisplatin has several major drawbacks. Driven by the impressive impact of cisplatin on cancer chemotherapy, great efforts have been made to develop new derivatives with improved pharmacological properties. Among the over 30 platinum agents which have entered clinical trials after the onset of clinical studies with cisplatin in the early 1970s, only carboplatin and oxaliplatin have received worldwide approval so far, nedaplatin, lobaplatin and heptaplatin have gained regionally limited approval. It has become quite evident that mere analogues of cisplatin or carboplatin will not probably offer any substantial clinical advantages over the existing drugs. Therefore, people turned to synthesize non-classical platinum anticancer drugs which were capable of forming a different range of DNA adducts which could display a different spectrum of anticancer activity compared to cisplatin. This review will summarize the structural types and structure-activity rules of non-classical bi- and multi-nuclear platinum anticancer drugs, and discuss their future potential as anticancer agents.
Export Options
About this article
Cite this article as:
Zhang Jinchao, Wang Liwei, Xing Zhiyong, Liu Dandan, Sun Jing, Li Xiaoliu and Zhang Ying, Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (4) . https://dx.doi.org/10.2174/187152010791162270
DOI https://dx.doi.org/10.2174/187152010791162270 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Current Medicinal Chemistry Calcium and Zinc DTPA Administration for Internal Contamination with Plutonium-238 and Americium-241
Current Pharmaceutical Biotechnology Modified Polysaccharides as Carriers for Biomolecules
Pharmaceutical Nanotechnology Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Targets for Steroid Hormone Mediated Actions of Periodontal Pathogens, Cytokines and Therapeutic Agents Some Implications on Tissue Turnover in the Periodontium
Current Drug Targets Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Effectiveness of Two Novel Anionic and Cationic Platinum Complexes in the Treatment of Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Exploiting Microwave-Assisted Organic Synthesis (MAOS) for Accessing Bioactive Scaffolds
Current Organic Chemistry The Influence of DNA Methylation on Bone Cells
Current Genomics Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Inorganic Phosphate as a Signaling Molecule: A Potential Strategy in Osteosarcoma Treatment
Current Pharmaceutical Design The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma
Current Cancer Drug Targets Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Fluid-fluid Levels in Musculoskeletal Tumor Imaging
Current Medical Imaging Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design